Loading... (0%)

News + Events

news

3-V Biosciences to Present Data at the 18th ECCO – 40th ESMO European Cancer Congress in Vienna

17 September 2015

Menlo Park, California, September 17, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology, announced today that it will present data from its ongoing Phase 1 clinical study at the 18th ECCO – 40th ESMO European Cancer Congress to be held September 25-29 in Vienna, Austria. The late-breaking abstract titled “Evidence of…

3-V Biosciences to Present at the 2015 Wedbush PacGrow Healthcare Conference on August 12, 2015

04 August 2015

Menlo Park, California, July 5, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, announced today that it will present at the 2015 Wedbush PacGrow Healthcare Conference in New York, NY. Merdad Parsey, Chief Executive Officer, is scheduled to present on Wednesday, August 12th at 1:55p.m. ET. About 3-V…

3-V Biosciences Provides Clinical Update on TVB-2640 at AACR Metabolism and Cancer Conference

09 June 2015

Menlo Park, California, June 9, 2015: 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, is pleased to announce that new data from its ongoing Phase 1 Study of its lead program (TVB-2640), a first-in-class Fatty Acid Synthase (FASN) inhibitor were presented at the AACR Metabolism…